Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 04/15/2005 (Other)

Filing Date: December 13, 2002

According to a press release dated April 11, 2005, Cytyc Corporation, a leading women's health company, announced that United States District Judge Nathaniel M. Gorton had dismissed the consolidated federal securities class action lawsuit that had been pending against Cytyc and a current and former officer in the United States District Court for the District of Massachusetts. In dismissing the lawsuit, Judge Gorton accepted and adopted the recommendation of United States Magistrate Judge Marianne B. Bowler that the District Court dismiss the case without prejudice for reasons set forth in her comprehensive, 73-page, decision on defendants' motion to dismiss. Plaintiffs' counsel has confirmed that plaintiffs will not appeal the Court's ruling, and will not file a further amended complaint or take any other action to continue the prosecution of their claims.

The complaint charges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, by issuing a series of materially false and misleading statements to the market between July 25, 2001 to June 25, 2002. Among other things, the complaint alleges that throughout the Class Period Cytyc issued press releases representing that it was enjoying record revenue and earnings growth, increasing the market share of its primary product (ThinPrep), that its revenues would grow by 25% in 2002 over 2001, to 300 million, and that the Company was not negatively impacted, and would not be negatively impacted, by the general economic slowdown that was well underway at the time. These statements were materially false and misleading, according to the complaint, because they failed to disclose that the Company's seemingly-impressive revenue and earnings growth was attributable, in material part, to overstocking of inventory at the laboratories which purchased ThinPrep in large volumes in reaction to deep discounts offered by Cytyc (which recognizes revenue upon shipment). The complaint further alleges that defendants were motivated to commit the alleged securities laws violations in order to pump up the Company's results so that it could use its inflated stock as currency for key corporate acquisitions. On December 3, 2001, Cytyc acquired Pro-Duct Health, Inc. for $167 million in Cytyc common stock and cash and, on February 2, 2002, announced that it has entered a definitive merger agreement to acquire Digene Corporation using Cytyc common stock and cash. At the time of the announcement, the Digene acquisition was valued at $554 million. On April 24, 2002, after the close of trading, Cytyc revealed, in a conference call, that its revenues and earnings for 2002 would be materially less than the market had been led to believe. Instead of revenues between 305 million, the Company stated 2002 sales would be as low as $270 million, and reduced earnings expectations from $0.66 per share to 0.55 per share. According to the Company, the cut was due to inventory reduction by its customers (laboratories), which had overstocked ThinPrep in the first quarter of 2002 and would meet end-user demand from inventory instead of new orders. In response to the announcement, which was contrary to repeated assurances by the Company, the price of Cytyc common stock plummeted by 36.5%, falling from a $24.80 per share close on April 24 to close at $15.73 on April 25, on extremely heavy trading volume. The truth regarding the Company's business, however was still undisclosed, according to the complaint. On June 25, 2002, Cytyc shocked the market by again lowering its expected revenues for 2002 to $230- $245 million and earnings per share to $0.40- $0.44. In a conference call held later that day, Cytyc announced that it was considering switching its revenue recognition model from its current recognition-on-shipment to a system more reflective of end-user demand. In response, Cytyc's stock price plummeted again, this time by 39%, falling from a $11.46 per share close on June 24, to close at $6.88 per share on June 25, on extremely heavy trading volume.


Sector: Technology
Industry: Scientific & Technical Instr.
Headquarters: United States


Ticker Symbol: CYTC
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Massachusetts
DOCKET #: 02-CV-12399
JUDGE: Hon. Joseph L. Tauro
DATE FILED: 12/13/2002
CLASS PERIOD END: 06/25/2002
  1. Law Offices of Marc S. Henzel (Lawrence)
  2. Milberg Weiss Bershad Hynes & Lerach LLP (New York, NY)
  3. Moulton & Gans LLP
No Document Title Filing Date
COURT: D. Massachusetts
DOCKET #: 02-CV-12399
JUDGE: Hon. Joseph L. Tauro
DATE FILED: 08/26/2003
CLASS PERIOD END: 06/25/2002
  1. Gilman & Pastor LLP (Saugus)
    Stonehill Corporate Center 999 Broadway Suite 500, Gilman & Pastor LLP (Saugus), MA 01906
    781.231.7850 781.231.7840 ·
  2. Milberg Weiss Bershad & Schulman LLP (New York)
    One Pennsylvania Plaza, 49th Floor, Milberg Weiss Bershad & Schulman LLP (New York), NY 10119
    212.594.5300 212.868.1229 ·
  3. Milberg Weiss Bershad Hynes & Lerach LLP (New York, NY)
    One Pennsylvania Plaza, Milberg Weiss Bershad Hynes & Lerach LLP (New York, NY), NY 10119-1065
    212.594.5300 ·
  4. Moulton & Gans LLP
    133 Federal Street, Moulton & Gans LLP, MA 2110
    617.369.7979 ·
  5. Schiffrin & Barroway LLP
    3 Bala Plaza E, Schiffrin & Barroway LLP, PA 19004
    610.667.7706 610.667.7056 ·
  6. Shapiro Haber & Urmy LLP (Boston)
    75 State Street, Shapiro Haber & Urmy LLP (Boston), MA 02109
    617.439.3939 617.439.0134 ·
No Document Title Filing Date
—Related District Court Filings Data is not available